Fig. 6

Risk to overlook patients with residual neuromuscular blockade with a TOFR <0.9 and TOFR <0.7 when assessed with either uncalibrated acceleromyography (AMG), the algorithm of clinical muscle function tests, or tactile fading following peripheral nerve stimulation (PNS). The lines represent the mean risk to overlook residual neuromuscular blockade as a function of its prevalence. Exemplarily, the risks (bars are the 95% confidence intervals) are marked based on the prevalence found by Debaene et al. [25] Cammu et al. [15] and Murphy et al. [18]